Fatty acid binding protein 3(FABP3) regulates n-3 and n-6 polyunsaturated fatty acids(PUFAs) transportation in mouse trophoblast by Md Ariful, Islam

Fatty Acid Binding Protein 3 (FABP3) Regulates n-3 and n-6 





Department of Organ Anatomy 
Yamaguchi University Graduate School of Medicine 
Dissertation submitted in partial fulfillment of 
the requirements for the degree of Doctor of Philosophy in the 
Department of Organ Anatomy, 
Yamaguchi University Graduate School of Medicine 
Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, JAPAN. 
Nov. 2014 
ABSTRACT 
Deficiency of placental fatty acid transport during the embryonic period has been 
suggested to result in fetal developmental disorders and in various adult metabolic 
diseases. In this study, we examined the localization and functional significance of fatty 
acid binding protein (FABP), a cellular chaperone of fatty acids, in mouse placenta. 
Four FABPs (FABP3, FABP4, FABP5 and FABP7) were expressed with spatial 
heterogeneity in placenta, and FABP3 was dominantly localized to the trophoblast cells.
In placenta from Fabp3 gene-ablated mice, the transportation coefficient for n-6 
polyunsaturated fatty acids (PUFA) [n refers to polyunsaturated fatty acid] was reduced 
by 25 % (P < 0.01) and 44% (P < 0.001) at embryonic days 15.5 (E15.5) and E18.5 
respectively, while that for n-3 PUFAs was reduced by 19 % (P < 0.05) and 17 % (P < 
0.05) respectively. Accumulation of both n-3 and n-6 PUFAs in Fabp3 gene-ablated 
fetus was also reduced on days E15.5 and E18.5. In contrast, saturated fatty acid 
transportation and accumulation was unaffected in gene-ablated mice. An in vitro study 
using a trophoblast cell line (BeWo) also demonstrated that incorporation of n-6 and n-3 
PUFAs, but not saturated FAs, was significantly (P < 0.01) down-regulated in FABP3
knock-down BeWo cells. Glucose transportation and utilization was significantly 
up-regulated in both the in vivo and in vitro studies. These findings suggest that FABP3 
controls PUFA trafficking in trophoblast, strongly indicating that FABP3 is associated 
with pathophysiology of fetal developmental disorders and adult metabolic/psychiatric 
diseases. 
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1. INTRODUCTION 
1.1 Placenta: the vital temporary organ of mammals 
The placenta represents a key organ for fetal growth as it acts as an interface between 
mother and fetus regulating the fetal-maternal exchange of nutrients, gases, water, ions, 
and waste products; moreover, it is capable of metabolic, immunologic, and endocrine 
functions to support successful pregnancy. It plays a key role in fetal programming by 
directly regulating nutrients (including fatty acids) supply and fetal normal growth. It is 
essential for sustaining the growth of the fetus during gestation, and defects in its 
function result in fetal growth restriction or, if more severe, fetal death. In addition, it 
produces hormones that alter maternal physiology during pregnancy and forms a barrier 
against the maternal immune system (Cross et al., 2003). 
In humans and rodents, the fully developed placenta is composed of three major 
layers: the outer maternal layer, which includes decidual cells of the uterus as well as 
the maternal vasculature that brings blood to/from the implantation site; a middle 
“junctional” region, which attaches the fetal placenta to the uterus and contains 
fetoplacental (trophoblast) cells that invade the uterine wall and maternal vessels; and 
an inner layer, composed of highly branched villi that are designed for efficient nutrient 
exchange (Rossant et al., 2001). The villi are bathed by maternal blood and are 
composed of outer epithelial layers that are derived from the trophoblast cell lineage 
and an inner core of stromal cells and blood vessels.
Figure 1: Structure of mouse placenta with it’s different compartment (zone) 
Placental biology is now being focused by many researchers in relation to the 
impact of nutrients including fatty acids, amino acids, glucose, growth factors etc on 
fetal tissue/organ development and their ultimate impact on childhood as well as adult 
diseases (metabolic or psychiatric). Fetal growth is closely related to the capacity of the 
placenta to transport nutrients, which is dependent on the expression and activity of 
specific transporter proteins on the syncytiotrophoblast (Jansson et al., 2009; Sibley 
2009). 
Abnormal embryonic or fetal nutrition can lead to deleterious consequences in adult 
life (Barker 2006; Barker et al., 2006; Fowden et al., 2006) and it has been suggested 
that there is a strong association between low birth weight and the risk of developing 
type 2 diabetes mellitus(Hales et al., 1991; Ravelli et al., 1998) and cardiovascular 
disease(Barker et al., 1986; Barker et al., 1989) in adulthood. 
1.2 Polyunsaturated fatty acids (PUFAs) and cell biology 
Mammalian cells utilize three main types of fatty acids (FAs): (1) saturated FAs, which 
do not contain any double bonds; monounsaturated FAs (MUFAs), which contain a 
single double bond; and polyunsaturated FAs (PUFAs), which contain multiple double 
bonds. Among them PUFAs are important biological constituents having metabolic, 
structural, and signaling roles. The developing fetus requires substantial amounts of 
fatty acids to support rapid cellular growth and activity and among them; the n-3 (also 
termed as -3) and n-6 ( -6) PUFAs are crucial (Haggarty 2010). The most biologically 
important n-3 and n-6 PUFAs are eicosapentaenoic acid (EPA; 20:5n-3), 
docosahexaenoic acid (DHA; 22:6n-3), dihomo gamma linolenic acid (20:3n-6), and 
arachidonic acid (AA; 20:4n-6) (Haggarty 2010). While these PUFAs are metabolic 
derivatives of the essential fatty acids, -linolenic acid (ALA), and linoleic acid (LA), 
their formation from these precursors is energetically demanding and so they are most 
readily obtained from the diet. 
Figure 2: Structure of n-3 and n-6 PUFAs
Unlike plants, mammals are not able to synthesize the parent compounds of 
both fatty acid families, the n-6 fatty acid LA and the corresponding n-3 fatty acid ALA. 
Therefore, they must be obtained through the consumption of food. In contrast, 
mammals are capable of synthesizing the long-chain derivatives of these fatty acids, in 
particular AA, EPA and DHA, based on LA and ALA in a multistage conversion 
process, which primarily takes place in the endoplasmic reticulum of liver cells 
(Clandinin et al., 1981; Schuchardt et al., 2010). Because the placental desaturase 
activity/fetal enzyme activity is limited in utero, the fetus depends on placental PUFAs 
transfer (Hanebutt et al., 2008; Cetin et al., 2009). High amounts of DHA are 
incorporated into brain/retinal membranes and modulate membrane fluidity and 
permeability, improve photoreceptor differentiation and may impact on enzyme activity, 
respectively (Larque et al., 2002). 
1.3 Fatty acid binding proteins (FABPs): chaperone of fatty acids
Fatty acid-binding proteins (FABPs) constitute a multi-gene family of intracellular FA 
carrier molecules with low molecular masses of approximately 14–15 kDa. Multiple 
FABP isoforms (FABP1–12) have been isolated from distinct tissues. FABPs are 
generally believed to promote cellular FA uptake and transport toward specific 
metabolic pathways, and regulate gene transcription by delivering FAs as the ligands for 
specific nuclear receptors (Owada 2008). 
Figure 3: Schematic presentation of the cellular FABP function. The mechanism of 
uptake of fatty acids is facilated by membrane associated proteins, i.e. FATP and FAT 
(CD36). Intracellularly, fatty acids are bound by FABP, and FABP modulates various 
cellular processes including synthesis of acyl-CoA or eicosanoids. FA-mediated signal 
transduction and nuclear transcript by PPAR.
FA, fatty acid; FAT, fatty acid translocase (CD36); FATP, fatty acid transport protein; 
PPAR, peroxisome proliferator activated receptor; RA, retinoic acid; RXR, retinoid X 
receptor. Produced from (Owada, Y. 2008).
Owada, Y. 2008 
Figure 4: Phylogenetic tree of human fatty acid binding proteins. The bootstrap 
neighbor-joining phylogenetic tree was constructed using CLUSTAX. The human 
lipoclalin1 protein sequence (LCN1, GenBank accession number NP_002288) was used 
as an outgroup. The bootstrap values (based on number per 1000 replicates) are 
indicated on each node. The four phylogenetically-related FABPs with placenta 
expression was highlighted. Amino acid sequences of human FABPs were modified and 
reproduced from Godbout group (Liu et al., 2010).
Thus far, among the FABP family, FABP1, FABP3, FABP4, FABP5, and FABP7 have 
been observed to occur in both the human and rodent placenta (Watanabe et al., 1991; 
Das et al., 1993; Masouye et al., 1997; Knipp et al., 2000; Daoud et al., 2005; Larque et 
al., 2006; Biron-Shental et al., 2007). However, the precise localization of each FABP 




















Structurally, AA and DHA are key components of neuronal membranes, 
making up 15–20% of the brain’s dry mass and more than 30% of the retina 
(Richardson 2004). In early life, both n-3 and n-6 PUFA are critical for supporting brain 
growth and maturation. AA is crucial for brain growth, and mild deficiencies are 
associated with low birth weight and reduced head circumference (van de Lagemaat et 
al., 2011). It also plays a key role in the cellular processes underlying learning and 
memory (Das et al., 2003). DHA is particularly concentrated in highly active 
membranes such as synapses and photoreceptors, and adequate supplies are essential for 
normal visual and cognitive development (Neuringer et al., 1994; Uauy et al., 2001). 
Pre-formed PUFAs are found naturally in breast milk, and although some controlled 
studies have shown advantages to both visual and cognitive development from their 
addition to infant formula (Willatts et al., 2000). 
1.4. Aim of this research 
The aim of this research was to study the localization of FABP family in rodent placenta 
and functional role of dominant FABP family member, FABP3 with special 
consideration to the properties that are unique within the FABP family i.e. intracellular 
transportation of PUFAs in trophoblast cells. 
Figure 5: Possible molecular mechanism of FA transport with the help of 
FABPs in trophoblast cells.
Through this work, we hoped to reveal the molecular mechanism of PUFAs 
transportation in prenatal stage to explain the phenomena of fetal/adult developmental 
disorders pertaining to the mechanism of action and biological significance of FABP3 in 
the rodent placenta. We also hoped to be able to apply this knowledge to better our 
understanding of the roles of the other members of FABP family in general, as well as 
their potential FABP3-like functions in the placentas of non-rodent mammals. 
Fetal tissues 
MATERIALS AND METHODS 
2.1 Animals. Fabp3-knockout (Fabp3/) mice (Binas et al., 1999) and wild-type 
(Fabp3+/+) C57BL/6J mice were housed in a 12-h light/12-h dark cycle with ad 
libitum access to a standard rodent chow and water. At 8 weeks of age, both the 
Fabp3-KO and wild-type female mice were mated with male counterparts. For the 
preparation of chimeric placenta, a CAG-EGFP male mouse was mated with a wild-type 
female mouse (Fig. 6). C57BL/6-Tg [CAG-EGFP] mice were kindly supplied by Dr. 
Masaru Okabe (Osaka University, Osaka, Japan). The presence of a vaginal plug was 
designated as embryonic day 1 (E1). At E11.5, E15.5, and E18.5, dams were killed and 
placentas were collected. All experimental protocols were reviewed by the Ethics 
Committee for Animal Experimentation of Yamaguchi University School of Medicine, 
Japan. 
Figure 6: Chimeric placenta preparation paradigm
2.2 Cells. BeWo cells (ATCC, CCL-98) were cultured in Ham’s F12 K medium (Wako, 
Osaka, Japan) with 10% fetal bovine serum (Hyclone, Logan, UT, USA) supplemented 
with 100 IU/mL penicillin-streptomycin (Wako, Osaka, Japan). The cells were routinely 
maintained at 37 °C in a 5% CO2 atmosphere. At confluency, the cells were 
sub-cultured using a 0.25% trypsin-EDTA (Life Technologies, Carlsbad, CA, USA) 
solution to suspend the cells.
2.3 Polymerase chain reaction (PCR) 
Total RNAs from the frozen placenta of wild-type mice were obtained using the trizol 
method for reverse transcription-PCR (RT-PCR). The cDNA was synthesized using 
ExTaq polymerase (Takara, Shiga, Japan). Expression levels of Fabps 1, 2, 3, 4, 5, 7 
(Murphy et al., 2005), 8 (Thumser et al., 2001), and 9 and -actin as the internal control 
(Iyoda et al., 2002) were examined by RT-PCR with the primers listed in Table 1. PCR 
amplification was performed using a programmed temperature control system (PCR 
thermal cycler TP600/650, Takara, Shiga, Japan). PCR products separated on 2% 
agarose gel were visualized by ethidium bromide staining and photographed under 








Fabp4 F (TCAACCTGGAAGACAGCTCCT) 
R (TCGACTTTCCATCCCACTTC) 
Fabp5 F (CAAACCGAGAGCACAGTGA) 
R (TTTGACCGCTCACTGAATTG) 
Fabp7 F (GGGTAAGACCCGAGTTCCTC) 
R (GAGCTTGTCTCCATCCAACC) 
Fabp8 F (CAACAGAAAAGCCAAGCGCA) 
R (CCAGAACAAAGCTCTTACCTTC) 
Fabp9 F (GGTTTTCGGTTGTGAATGCC) 
R (GCTACACCCTTTCGTAGATCC) 
-actin F (CAGGAGATGGCCACTGCCGCA) 
R (CTCCTTCTGCATCCTGTCAGCA) 
Table 1. Primer sequences used for standard PCR expression analysis. 
2.4 Real time-PCR (RT-qPCR). For quantitative PCR (qPCR) analysis, total RNA was 
extracted from the E15.5 and E18.5 placenta (of wild-type and Fabp3-KO mice) and 
cells using an RNeasy Protect Mini kit and Micro kit (Qiagen, Valencia, CA, USA) then 
treated with ribonuclease-free deoxyribonuclease according to the instructions of the 
manufacturer (Qiagen). The quantity of the total RNA was assessed by UV 
spectrophotometer (DU 640; Beckman Coulter, Boulevard, CA, USA). RT was 
accomplished using a high fidelity reverse transcriptase cDNA synthesis kit (Roche, 
GmbH, Mannheim, Germany) following the manufacturer’s protocol. Real-time PCR 
was performed using a Taqman Fast Universal PCR Master Mix kit (Applied 
Biosystems, Branchburg, NJ, USA) and reactions were performed in triplicate using 
96-well optical plates on a Step One Plus Real-Time PCR System (Applied Biosystems, 
Foster city, CA, USA). Among the target genes (Table 2 and 3), the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used as an internal control. 
Data were analyzed within the log linear phase of the amplification curve obtained for 
each probe or primer using the comparative threshold cycle method (Applied 
Biosystems). The thermal cycle conditions used were as follows: 45 cycles of 95 °C for 
15 s, 60 °C for 1 min using 100 ng/well of cDNA in a final reaction volume of 20 L. 






p-Fabppm (got2) Mm00494703_m1 
Fat (Cd36) Mm01135198_m1 
Gapdh Mm03302249_g1 
Table 2. Primer sequences used for RT-qPCR expression invivo analysis. 







pFABPpm (GOT2)  Hs00905827_g1 
FAT (CD36) Hs01567185_m1 
GAPDH Hs99999905_g1 
Table 3. Primer sequences used for RT-qPCR expression invitro analysis. 
2.5 Western blotting. The expression of FABP3, FABP4, and FABP5 proteins was 
analyzed in placental homogenates. Placenta were homogenized and suspended in cold 
2xSDS-PAGE sample buffer containing protease inhibitors (Roche Diagnostics, 
Mannheim, Germany). Twenty micrograms of protein were resolved by SDS PAGE 
(15% gel) and immunoblotted onto a polyvinylidene difluoride membrane (Millipore, 
Billerica, MA, USA). The membrane was blocked by soaking in blocking solution [5% 
nonfat dried milk in Tris-buffered saline with 0.1% Tween 20 (TBST)] for 1 h and 
incubated at 4° C overnight on a rocking platform with specific antibody: anti-FABP3 
[0.5 g/mL dilution, (Guthmann et al., 1998)], anti-FABP4 [0.5 g/mL dilution, 
(Abdelwahab et al., 2007)], anti-FABP5 [0.5 g/mL dilution, (Owada et al., 2002)], or 
anti-GAPDH (1:500; Santa Cruz Biotech, Santa Cruz, CA, USA) as the internal control. 
The membrane was then washed three times with TBST, and incubated with 1:1000 
horseradish peroxidase-conjugated goat anti-rabbit IgG (Chemicon, Temecula, CA, 
USA) for 1 h at room temperature, and then the signals were visualized by the 
ECL-Western Blotting Detection System. 
2.6 Laser capture microdissection (LCM) of the labyrinthine compartment. The 
localization of Fabp3, Fabp4, and Fabp5 mRNA was also examined by RT-PCR in the 
placental labyrinthine compartment using LCM. Whole mouse placenta was collected at 
E18.5 using sterile apparatus. All specimens were frozen in cryomold in an 
isopentene-dry ice bath and stored at 80 °C until slicing. Following cryosectioning 
(CM 1850; Leica, Wetzlar, Germany), sections were captured on RNase-free slides 
(PEN-membrane; Leica) and placed immediately on dry ice. Staining and dehydration 
were performed using LCM-certified solutions provided in the histogene frozen section 
staining kit (Arcturus, Mountain View, CA, USA). Briefly, slides were fixed and 
dehydrated with solutions of 75% ethanol, 95% ethanol, 100% ethanol, and xylene and 
stained with RNase-free staining solution. The labyrinthine compartment was cut and 
collected using the Laser Microdissection (LMD) system (LMD 6500; Leica) under the 
following conditions: laser output power 35 mV; laser beam size 15 m; laser power 
exposure duration 24 s; and the sample was collected in a 0.5- L single tube. Total 
RNA was extracted from the tissue using an RNeasy Micro kit (Qiagen, Valencia, CA, 
USA) and cDNA was amplified using a Transcriptor High Fidelity cDNA synthesis Kit 
(Roche, GmbH). Fabp3, Fabp4, Fabp5, and Fabp7 mRNA expression levels were 
analyzed using primer sets (Table 1). 
Figure 7: Schematic diagram of LCM system for collection of labyrinthine 
compartment of mouse placenta. 
2.7 Immunohistochemistry. Placenta were removed after transcardiac perfusion with 
4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4), cryoprotected with 30% 
(w/v) sucrose in 0.1 M phosphate buffer and then embedded into the freezing medium 
(OCT compound; Sakura Finetek, Torrance, CA, USA). Cryosections (20 m thickness) 
were cut with a cryostat (CM 1850; Leica). The sections were then incubated with 
rabbit polyclonal primary antibodies for FABP3, FABP4, FABP5, or FABP7 (dilution 
0.5 g/mL) overnight at 4 °C, and subsequently with the biotinylated anti-rabbit 
secondary antibody (Vector Laboratories, Burlingame, CA, USA). The immunoreaction 
sites were visualized using the avidin-biotinylated peroxidase complex (ABC) system 
(Vector Laboratories) with 3, 3-diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich, St. Louis, MO, USA) as a substrate. For double-immunofluorescence 
staining, sections (12 m) were incubated with FABP3, FABP5, and chicken anti-rat 
monocarboxylated transporter 1 [MCT1, 1:200, (Chemicon, Temecula, CA, USA)] 
antisera followed by incubation with goat anti-rabbit IgG Alexa 488 (1:1000; Invitrogen, 
Carlsbad, CA, USA) and goat anti-chicken IgG Alexa 594 (1:250; Invitrogen). After 
counterstaining of the nuclei with diamidino-2- phenylindole (DAPI), the cells were 
covered with Gel Mount (Biomeda, Foster City, CA, USA) and observed using a 
confocal laser microscope (LSM510 META; Carl Zeiss, Oberkochen, Germany). For 
immunofluorescence staining of the chimeric placenta, the placenta was collected using 
the same procedure as above. Sections (12 m) were incubated with FABP3, FABP5, 
and FABP7 antisera, followed by incubation with goat anti-rabbit IgG Alexa 568 
(1:1000; Invitrogen). For the immunohistochemistry of human placenta, human 
full-term placenta (obtained by Cesarean section, Yamaguchi University Hospital, 
Yamaguchi, Japan) formalin-fixed, paraffin-embedded sections (6 m) were prepared. 
The sections were then incubated with a mouse monoclonal anti-human FABP3 
antibody (0.5 g/mL, DS Pharma Biomedical, Osaka, Japan) overnight at 4 °C, washed, 
and the bound antibodies were detected with a biotinylated anti-mouse secondary 
antibody (Vector Laboratories, Burlinegame, CA, USA). The immunoreaction sites 
were visualized using the ABC system with DAB as a substrate. 
Antibody table 
























Yuji Owada Rabbit, 
polyclonal 
0.5 g/ml




Yuji Owada Rabbit, 
polyclonal 
0.5 g/ml








































Yuji Owada Mouse 
monoclonal 
0.5 g/ml







Table 4: List of antibodies used in immunohistochemistry and western blotting. 
2.8 Morphometric analysis of placenta. Placentas were sampled from either wild-type 
or Fabp3-KO mice and then morphologically compared to investigate any abnormalities 
between these groups. First, placentas and fetuses from either wild-type or Fabp3-KO 
mice (for E15.5, litter size six and for E18.5, litter size four), were obtained, then 
placental and fetal weight were measured. For microscopic observations, placentas from 
either wild-type or Fabp3-KO mice at E18.5 were fixed overnight at 4 °C in fresh 4% 
paraformaldehyde/PBS, dehydrated, and embedded in paraffin. Sections (6 m) were 
prepared by microtome and stained with hematoxylin and eosin. 
2.9 Analysis of placental transport of radiolabeled FAs and glucose. Placental 
transport of radiolabeled FAs and glucose was examined as described previously by 
Bloise et al. (Bloise et al., 2012) with slight modifications. Experiments were conducted 
at E15.5 and E18.5, when rapid fetal growth and active nutritional transport are 
observed in the mouse placenta (Coan et al., 2010). Briefly, Fabp3+/ mice were 
intercrossed (Figure 5), and anesthetized (Isoflurane; Abbott, Chicago, IL, USA) using a 
small animal anesthetizer (Muromachi Co., Tokyo, Japan) at E15.5 and E18.5. Then, the 
maternal jugular vein was exposed and total of 100 L of PBS containing 3.5 Ci of 
[1-14C]-linoleic acid (LA,18:2n-6), (NEC-501; specific activity 58.2 mCi/mmol, Perkin 
Elmer, Waltham, MA, USA), 9,12,15-[1-14C]-linolenic acid (ALA,18:3n-3), (NEC-779; 
specific activity 51.7 mCi/mmol, Perkin Elmer), [1-14C]-palmitic acid (PA,16:0), 
(NEC-075H; specific activity 60 mCi/mmol, Perkin Elmer), or D-[14C(U)]-glucose 
(GLU), (NEC-042X; specific activity 289 mCi/mmol, Perkin Elmer) was injected in the 
jugular vein via a short piece of tubing (15 cm) attached to a 27-gauge needle. 
Figure 8: Fabp3+/- mouse preparation paradigm
Maternal blood samples (0.30.7 mL) were collected from the heart after 4 min of 
radioisotope injection (Constancia et al., 2002) to measure the maternal plasma 
radioactivity after cervical dislocation; studies have shown there is minimal tracer 
backflux at this time (Sibley et al., 2004). Fetuses and placentas were then dissected out 
and weighed. Fetuses were minced and lysed for 5 h at 55 °C in Solvable (Perkin 
Elmer). A small section of tail was collected from each fetus for genotyping. The liquid 
scintillation cocktail (LSC), Ultima Gold (Perkin Elmer) was then added to aliquots of 
maternal plasma and fetal fractions in scintillation tubes (Perkin Elmer) for -counting 
(liquid scintillation counter 5100; Aloka, Tokyo, Japan). The transfer of radioactive 
material from mother to fetus was evaluated following the method previously described 
by Constancia et al. (Constancia et al., 2002). Briefly, radioactive counts detected in 
each fetus were used to calculate the amount of radioactive material transferred per 
gram of placenta or per whole embryo. Average values for wild-type and mutant fetuses 
within a litter were then calculated and expressed as a ratio of mutant to wild type.
2.10 Stealth RNAi-mediated knockdown. BeWo cells were plated in 12-well plates and 
maintained overnight in Hams F-12 K medium containing 10% fetal bovine serum 
(Hyclone). After incubation for 24 h, stealth RNAi directed against the human FABP3 
mRNA [Oligo ID: HSS103512 (Invitrogen, Carlsbad, CA, USA)] was used for FABP3 
knockdown. Non-targeting low GC content stealth RNAi (ID:46-2002; Invitrogen, 
Carlsbad, CA, USA) was used as a control (scramble control). Transfection experiments 
were performed according to the manufacturers instructions. Stealth RNAi in 
OptiMEM (Gibco, Carlsbad, CA, USA) was mixed with Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) at room temperature for 15 min. After incubation for 
48 h, FABP3 knockdown was confirmed by quantitative real-time PCR and western 
immunoblotting. 
Figure 9: Schematic diagram of FABP3-knockdown BeWo cell preparation
2.11 Morphology and proliferation assay of FABP3-knockdown BeWo cells: The 
morphological characteristics and apoptosis of BeWo cells were checked after FABP3
knockdown at 24 hours and 48 hours by visual assessement. For proliferation assay 
BrdU staining was performed. BrdU (10 M) was added to culture medium at 2 days 
after seeding when the cells reached a subconfluent state, and was incubated for 5 h. 
BrdU+ cells were visualized immunocytochemically using an anti-BrdU antibody as 
described previously with slight modifications (Sharifi et al., 2011). Briefly, cells were 
incubated with 2 M HCl at room temperature for 30 min followed by washing twice 
with 0.1 M sodium borate (pH 8.5) over 10 min. After blocking with 5% goat serum at 
room temperature for 30 min, they were incubated with mouse anti-BrdU antibody 
(1:100) at 4 C overnight, and incubated with anti-mouse IgG-Alexa488 (1:1000) at 
room temperature for 1 h and then counterstained with DAPI. After several washes with 
PBS, they were mounted and cover slipped. 
2.12 FA uptake assay. Cellular uptake of FAs and glucose was examined in BeWo cells, 
as described previously (Sharifi et al., 2011). Briefly, after cells became confluent in 
12-well plates, 14C-labeled LA, ALA, PA, or GLU (0.1 Ci/mL) were added to FABP3 
knockdown (48 h) BeWo cells and incubated for 60 min. Cells were thoroughly washed 
with cold PBS to remove any surface-bound FAs. The cells were then lysed and 
harvested in Solvable (Perkin Elmer) and used for scintillation counting. The results 
were expressed as DPM/ g protein. Incubation with stealth RNAi and scramble control 
was performed 48 h before the FA uptake study.
2.13 Calculation and Statistics. Values for all data are expressed as means ± SEMs. For 
comparison of the base pair strength within the embryonic stage, one-way ANOVAs 
followed by Tukey comparison tests were performed, Fabp3 expression among the 
embryonic stages was also compared by same analysis. For compact and comprehensive 
presentation of placental in vivo transport studies, the one-sample t-test (Constancia et 
al., 2002) was used; for the in vitro FA study and qRT-PCR, data were analyzed using 
Student’s two-tailed unpaired t-test (SPSS software version 16.0). P values < 0.05 were 
considered statistically significant. 
RESULTS 
3.1 Expression of FABPs in the mouse placenta. We first examined the gene 
expression of the Fabp family from mid to late embryonic stages (E11.5, E15.5, and 
E18.5), because FA demand increases in the developing fetus with the progression of 
gestation. By semi-quantitative RT-PCR, Fabp3, Fabp4, and Fabp5 were found to be 
expressed in whole placentas at E15.5 and E18.5, with Fabp3 expression of the highest 
intensity (Fig. 10A). Other Fabp mRNA (Fabp1, Fabp2, Fabp7, Fabp8, and Fabp9) 
were not detected. 
Figure 10A: Identification of the Fabp family in the wild-type mouse placenta at mid to 
late embryonic stages; whole placenta were used to collect the mRNA, which was 
analyzed by semi-quantitative RT-PCR. -actin was used as the internal control. bp, 
base pair; Fabp, fatty acid binding protein. 
Levels of Fabp3 expression were significantly higher at E15.5 and E18.5, compared 
with E11.5 
Figure 10 B: Comparison of (means ± SEMs, n = 3 mouse dams) expression intensities 
of Fabp species from base pair intensity (image J software), a and x, P<0.001. AU, 
arbitrary unit; Fabp, fatty acid binding protein. 
To identify the Fabp molecule expressed in the labyrinthine compartment, which is the 
active compartment for nutrient transport (Watson et al., 2005), we dissected the 
labyrinthine compartment of mouse placenta at E18.5, using LCM and the mRNA was 
extracted. In RT-PCR analysis of the dissected samples, Fabp3 mRNA showed to be 
highly enriched in the labyrinthine compartment, while only faint to weak expression of 
Fabp4 and Fabp5 was detected (Fig. 10 C). 
Figure 10 C: Expression of Fabp3, Fabp4, Fabp5 and Fabp7 in the fetal labyrinthine 
layer. bp, base pair; Fabp, fatty acid binding protein. 
In western blot analysis, FABP3, FABP4, and FABP5 were confirmed to be expressed 
in mouse placenta at mid, mid to late and late stages of pregnancy (Fig. 10D)
Figure 10 D: Expression of FABP3, FABP4, and FABP5 in WT placenta. kDa, 
kilodalton.  
3.2 Spatially different distribution of FABPs in the mouse placenta. Immunostaining 
revealed that FABP3, FABP4, FABP5, and FABP7 expression is spatially different in 
the mouse placenta. Consistent with the results of mRNA expression analysis, FABP3 
was strongly localized in the labyrinthine compartment at E15.5 and E18.5 (Fig. 11, a 
and b). Conversely, FABP4 was dominantly localized in the spongiotrophoblast 
compartment, which is the supportive layer of the labyrinthine compartment (Rossant et 
al., 2001) (Fig. 11, d and e) and FABP5 was weakly, but evenly distributed over the 
whole placenta (Fig. 11, g and h). Unexpectedly, FABP7 was localized to some 
maternal vessels (sinusoids) of the labyrinthine compartment (Fig. 11, j and k). Similar 
results were obtained from the analysis of E11.5 placenta (data not shown). The 
placenta obtained from the corresponding gene knockout mice for FABP3, FABP5, and 
FABP7 did not show any immunoreaction (Fig. 11, c, f, and l) and the placenta stained 
with primary antibody omission for FABP4 (Fig. 11, i) also did not present any 
immunoreaction, suggesting the authenticity of the immunoreaction of these anti-FABP 
antibodies. 
Figure 11: Immunohistochemical localization of FABP3 in the fetal labyrinthine layer 
(a, b), FABP4 in the maternal decidua layer (d, e), FABP5 in the whole placenta (both 
fetal and maternal) (g, h), and FABP7 in the maternal sinusoids of the fetal 
labyrinthine layer (j, k) at E15.5 and E18.5 stages. Fabp3-KO (c), Fabp5-KO (i), and 
Fabp7-KO (l) mouse placental sections were used as negative control. A primary 
antibody-omitted section (f) was used as the negative control to confirm the FABP4 
expression in the mouse placenta. All antibodies were applied under the same 
conditions and concentrations. Red-colored insets are a higher-magnification image of 
the labyrinthine or decidua layer. Fabp, fatty acid binding protein; WT, wild-type; 
Fabp-KO, Fabp-knockout; L, labyrinthine layer; D, decidua layer, scale bar, 100 m. 
3.3 FABP3 is expressed in labyrinthine trophoblast cells. The placenta functions as a 
hybrid organ between the mother and fetus. The labyrinthine compartment is regarded 
as the transport compartment where the nutrient exchange mainly occurs. The 
labyrinthine compartment consists of maternal cells, labyrinthine trophoblasts, as well 
as fetal cells (Cross et al., 2002). To identify the FABPs that are expressed in 
labyrinthine trophoblasts, we first performed double immunofluorescence staining using 
the trophoblast marker, monocarboxylase transporter 1 (MCT1) (Nagai et al., 2010; 
Bonnin et al., 2011). FABP3 was abundantly localized in MCT1+ trophoblasts (Fig. 
12A and B) and its subcellular localization pattern was strikingly similar to that of 
MCT1, suggesting that FABP3 is associated with the apical membrane of trophoblasts. 
FABP5 was also weakly present in MCT1+ cells, while its distribution was confined to 
the cytoplasm. 
3.4 FABP3and FABP5 is expressed in human trophoblast cells. In addition to the 
localization of FABP3 and FABP5 in mouse placenta, we detected FABP3 and FABP5 
expression in the trophoblasts of human full-term placenta.
Figure 12 (A, B) Localization of FABP3 and FABP5 in the fetal labyrinthine 
trophoblast of the mouse placenta. Colocalization of FABP3 (A) and FABP5 (B) with 
MCT1+ (trophoblast marker) cells. As a negative control, Fabp3-KO and Fabp5-KO 
mouse placenta were used under the same conditions. WT, wild-type; Fabp-KO, 
Fabp-knockout; FABP, fatty acid binding protein; MCT1, monocarboxylase transporter 
1; DAPI, diamidino-2- phenylindole. Scale bar, 20 m.
Figure 13. Immunolocalization of FABP3 and FABP5 in human term placental villous 
(A and B). For negative control, the primary antibody was omitted under same 
conditions (C). Scale bar 10 m.
3.5 FABP3and FABP5 is expressed in fetal derived trophoblast cells. Next, to further 
confirm the localization of FABPs in fetal cells, we stained chimeric placenta obtained 
by mating a CAG-EGFP male mouse with C57BL/6 wild-type female mouse (Fig. 6). 
FABP3 and FABP5 were found to be co-localized with fetal-derived GFP+ cells. In 
contrast, FABP7 was localized in GFP- maternal vessels.  
FABPs expression table 
FABP Localization in placenta 
FABP3  trophoblast in labyrinthine compartment (fetal cells)  
FABP5  trophoblast in labyrinthine compartment (fetal cells). 
spongiotrophoblast (maternal cells),  
decidua compartment (maternal cells) 
FABP4 decidua compartment (maternal cells) 
FABP7 sinusoids of labyrinthine (maternal cells) 
Table 5. Summary of FABPs expression in mouse placenta
Figure 14: Localization of FABP3, FABP5 and FABP7 in WT-GFP chimera placenta. 
FABP3 and FABP5 immunopositivities were revealed to be overlapped (yellow) with 
GFP expression, confirming that both FABPs localize in fetal trophoblast cells, while 
FABP7 does not. WT-GFP chimera, chimeric placenta; FABP, fatty acid binding 
protein; DAPI,diamidino-2- phenylindole. Scale bar, 20 m.
Overall, FABP3 was the major FABP localized in the trophoblasts of mouse placenta, 
suggesting that it is likely to be involved in PUFA transport through the placenta. 
3.6 Fabp3 deficiency does affect the fetal gross appearance and weight. The fetus 
collected from wild type and Fabp3-KO at E18.5 stage did not display any variation in 
their gross appearance. Furthermore placental and/or fetal weights did not show any 
significant differences between these two groups. 
Figure 15: Comparison of feto-placental unit in visual appearance and weight variation 
at E18.5 (A, B). Placental and embryonic weight of both the wild-type and Fabp3-KO 
mice were measured from six litters (E15.5 stage) and four litters (E18.5 stage) (C, D). 
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3.7 Fabp3 deficiency does affect the histology of mouse placenta. We examined 
whether there were any morphometric differences between wild-type and Fabp3-KO 
placentas. Both of these groups did not present any macroscopic or microscopic 
abnormalities (Fig. 16A–D). Comparison of trophoblast count, maternal space and fetal 
space in the labyrinthine compartment was checked and did not display any significant 
difference between the experimental groups. 
Figure 16: Histological comparison of wild-type placenta with Fabp3-KO placenta. 
Cross-sections of the entire placenta at E18.5 (A, B) stained with hematoxylin and eosin. 
C, D shows high magnification image (scale bar, 50 m). 
3.8 No compensatory FA transporter gene is observed in Fabp3-KO placenta. To 
assess the influence of Fabp3 deficiency on placental expression of other reported fatty 
acid transporters, we initially interrogated the expression of Fabp and Fatp isoforms in 
the wild type and Fabp3-KO mouse placenta at E15.5 and E18.5. Changes in expression 
of genes involved in fatty acid transporters were assessed by RT-qPCR (Livak et al.,
2001). Samples were normalized to the house keeping gene Gapdh, which exhibited a 
stable expression in control or Fabp3-KO placenta. Importantly Fabp3 deficiency did 
not influence the expression level of Fabp4, Fabp5, Fatp1, Fatp4 (Garcia-Martinez et 
al., 2005; Larque et al., 2006), p-Fabppm (Campbell et al., 1997), Cd36 (fatty acid 
translocase, FAT) (Campbell et al., 1998) in mouse placenta (Fig. 16).  
Figure 17: Effect of Fabp3-ablation on the gene expression of major FA transporters in 
the mouse placenta at E15.5 (A) and E18.5 (B). Fabp3 deficiency did not affect the 
gene expression of other placental FA transporters. Gene expression was normalized by 
the amount of housekeeping gene (Gapdh). Fabp, fatty acid binding protein; Fatp, fatty 
acid transport protein; Fat (Cd36), Fatty acid translocase; p-Fabppm, placental-plasma 
membrane Fabp; Fabp3-KO, Fabp3-knockout; N.D., not detected (significant value was 
not detected in Fabp3-KO placenta by 40 cycles of PCR amplification). The values are 
the means ± SEMs (n = 3 mouse dams). 
This findings is supportive to the previous findings (Binas et al., 1999) where no 
compensatory expression of related fatty acid transporters in heart and skeletal muscle 
of Fabp3-KO mouse was observed.
3.9 PUFA traffic is impaired in the Fabp3-KO mouse placenta. We then sought to 
examine placental transport and fetal accumulation of long chain FAs in Fabp3-KO 
mice to explore the function of FABP3 in placental FA traffic. Interestingly, the 
placental transport of (n-6) and (n-3) PUFAs was significantly impaired in Fabp3-KO 
mice (both sexes): at E15.5 and E18.5, LA decreased by 25% (p < 0.01) and 44 % (p < 
0.001) and ALA decreased by 19% (p < 0.05) and 17% (p < 0.05), respectively, 
compared with wild-type mice (Fig. 18A). Furthermore, fetal accumulation of n-6 and 
n-3 PUFA was also significantly impaired in Fabp3-KO compared with wild-type mice: 
LA decreased by 18% (p < 0.05) and 27% (p < 0.01) at E15.5 and E18.5, respectively
(Fig. 18B) and ALA decreased by 16% (p < 0.05) at E15.5 (Fig. 18B). Fabp3
deficiency did not affect transport and accumulation of a saturated FA (palmitic acid)
(Fig. 18A and B). In contrast to the reduced PUFA transport and accumulation, glucose 
transport significantly increased by 23% (p < 0.01) at E18.5 in Fabp3-KO placenta (Fig. 
18A). These results are generally consistent with the reported phenotypes of 
Fabp3-deficient cardiac myocytes, including the impaired use of FAs and the increased 
reliance on carbohydrates to meet the cardiac energy demand (Schaap et al., 1999). 
Figure 18: Effect of Fabp3 ablation on placental transport and fetal accumulation of n-3 
and n-6 PUFAs. The placental transport (A) and fetal accumulation (B) of radiolabeled 
LA, ALA, PA, and GLU were expressed relative to placental or fetal weight and plotted 
as a ratio of Fabp3-KO to wild-type at two gestational ages (E15.5 and E18.5). 
Horizontal dashed line indicates standard value for which each bar is being compared to. 
Ratio < 1 and > 1 indicate ‘decreased’ and ‘increased’ transportation or accumulation in 
Fabp3-KO placenta or fetus, respectively. The data are presented here as means ± SEMs 
for each independent radioisotope, collected from six and four litters at E15.5 and E18.5, 
respectively. *, P < 0.05, **, P < 0.01, ***, P < 0.001. WT, wild-type; Fabp3-KO, 
Fabp3-knockout; LA, linoleic acid; ALA, -linolenic acid; PA, palmitic acid;, GLU, 
glucose.
3.10 Localization of FABP3 in BeWo cells. To further examine the role of FABP3 in 
trophoblast cells, we used human trophoblast cell line BeWo cells; which are 
extensively used as a human placental trophoblast cell model (Campbell et al., 1997; 
Tobin et al., 2009).
Figure 19: Localization of FABP3 in BeWo cells (B). Phase contrast image of BeWo 
cells (A).. E-Cadherin: marker of epithelial cells widely used to mark BeWo cells. 
FABP3 immunopositivities were revealed to be overlapped (yellow) with E-Cadherin 
expression, confirming that FABP3 localize in human trophoblast cell line (BeWo cells). 
3.11 FABP3 siRNA transfection successfully knockdown FABP3 mRNA and protein 
expression. To further examine the role of FABP3 in trophoblast cells, we transfected 
FABP3 siRNA into BeWo cells (Fig. 9). 48 h after siRNA transfection in BeWo cells 
successfully suppressed gene and protein expression of FABP3
Figure 20: The effect of FABP3 knockdown in BeWo cells by RT-qPCR (A) and 
Western blot analysis (B), GAPDH was used as the internal control. 
3.12 FABP3 siRNA transfection does not affect morphology and proliferation of 
BeWo cells. Then we checked if there any morphological alteration due to FABP3
siRNA knockdown following the protocol cited above (Fig. 9). Phase contrast images 
do not show any significant difference in morphology of FABP3-KD BeWo cells 
compared to scramble control (Fig. 21 A, B). Proliferation checking using BrdU uptake 
assay also revealed that FABP3 siRNA knockdown does not affect proliferation of 
BeWo cells.
Figure 21: The effect of FABP3-knockdown on the morphology and proliferation of BeWo 
cells (A, B). BrdU uptake properties of FABP3-KD BeWo cells compared to scramble 
control (C, D). 
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3.13 FABP3-KD does not affect the gene expression of placental other FA 
transporters in BeWo cells. Similar to invivo FA transporters in mouse placenta, the 
gene expression of other FA transporters (Table 3) in FABP3-KD BeWo cell does not 
significantly changes compared to scramble control.
Figure 22: Effect of FABP3-knockdown on the gene expression of major FA 
transporters in BeWo cells after 48 hours transfection. FABP3-KD did not affect the 
gene expression of other placental FA transporters. Gene expression was normalized by 
the amount of housekeeping gene (GAPDH). FABP, fatty acid binding protein; FATP, 
fatty acid transport protein; FAT (CD36), Fatty acid translocase; p-FABPpm,
placental-plasma membrane FABP; FABP3-KD, Fabp3-knockdown; N.D., not detected 
(significant value was not detected by 40 cycles of PCR amplification). The values are 
the means ± SEMs (n = 3 independent trials). 
3.14 PUFA uptake is impaired in FABP3 knockdown BeWo cells. To further examine 
the role of FABP3 in PUFA uptake invitro, we investigated the n-3 and n-6 PUFA 
uptake in FABP3-KD BeWo cells. As expected, uptake of LA and ALA was decreased 
in FABP3 knockdown BeWo cells, compared with the control (Fig. 23 A, B): LA 
uptake was decreased by 51% (P < 0.05) and 52% (P < 0.01) after 1 and 60 min of 
incubation, respectively. ALA uptake was also decreased by 23% (P < 0.05) after 60 
min of incubation. Similar to the in vivo analysis, GLU uptake was increased by 51% (P
< 0.01), 50% (P < 0.05), 31% (P < 0.05), and 33% (P < 0.05) at 1, 20, 40, and 60 min 
after incubation respectively (Fig. 23D). FABP3 knockdown in BeWo cells did not 
affect PA uptake (Fig. 23 C). 
Figure 23. Effect of FABP3-knockdown on n-3 and n-6 PUFAs uptake in BeWo cells. 
Bar graphs (A–D) show the incorporation of LA (A), ALA (B), PA (C), and GLU (D) in 
FABP3-Knockdown BeWo cells, compared with the scramble control. The amount of 
FA or GLU uptake was measured in DPM/ g protein of lysates up to 60 min. The 
graphs shown in A–D were representative ones from three independent trials performed 
in triplicate. Values are means ± SEMs, n = 3. Student’s t-test. *, P < 0.05, **, P < 0.01, 
***, P < 0.001. FABP3, fatty acid binding protein; AU, arbitrary unit; LA, linoleic acid; 
ALA, -linolenic acid; PA, palmitic acid; GLU, glucose; KD, fatty acid binding protein 
3 knockdown; BeWo, human choriocarcinoma cell line; kDa, kilodalton; DPM/ g, 
Disintegration per minute per microgram. 
DISCUSSION: 
Proper fetal development is dependent on sufficient nutrient supply to the fetus. 
Because substrate transport, including FAs, is directed from the maternal to the fetal 
circulation under physiological conditions, the placenta’s ability to facilitate this 
transport is of critical importance for the development of a healthy fetus (Knipp et al.,
1999). In this study, we identified FABP3 to be the major FABP expressed in mouse 
trophoblast cells and evaluated whether FABP3 deficiency may affect transplacental FA 
transport and placental/fetal development during late gestation. 
The mouse placenta is subdivided into three major compartments: the decidua, 
spongiotrophoblast, and labyrinthine compartments (Malassine et al., 2003; Watson et 
al., 2005). The labyrinthine compartment, which is bathed in maternal blood, is the 
main nutrient exchange layer between the mother and fetus (Rinkenberger et al., 2000) 
and includes both maternal and fetal cells. We have clearly shown the expression of 
FABP3 and FABP5 in trophoblast cells in the labyrinthine compartment, which are the 
epithelial cells responsible for the exchange of various nutrients (Jones et al., 2007). 
Regarding the molecular mechanism underlying FA transport from mother to 
fetus, triglycerides in lipoproteins are hydrolyzed by placental lipases in particular 
lipoprotein lipase, localized in the MVM (Lindegaard et al., 2005). As a result, free 
fatty acids are released, which either diffuse across the plasma membrane (Herrera et al.,
2006) or uptake occurs through fatty acid transport proteins (Dutta-Roy 2000). FFA 
transported into the syncytial cytoplasm bind to cytoplasmic FABP and are directed to 
different sites for esterification, beta-oxidation or for transport over to the fetus across 
the BM. Dutta-Roy group has previously identified p-FABPpm in BeWo cells and 
proposed the possible involvement of molecules including several membrane associated 
transporters (FATPs, CD36, and caveolin) and cytoplasmic FABPs (FABP3, and 
FABP1), all of which are associated with cellular FA trafficking process (Campbell et 
al., 1998; Dutta-Roy 2000). Furthermore, Schaiff et al. reported the elevation of FATP1, 
FATP4, CD36 and p-FABPpm expression in placenta after PPAR  agonist 
administration, in which long-chain FA uptake was markedly induced (Schaiff et al.,
2007). However, the direct evidence regarding the function of these molecules in 
placental FA transport has not so far been available. This study is the first investigation 
to validate the involvement of FABP3 in n-3 and n-6 PUFA transport in trophoblast 
cells using gene-ablated mice and gene knockdown techniques at cellular levels (Fig 24). 
Although the functional importance of FABP5 in placental FA transport should be 
investigated in further studies, it is interesting to propose that saturated FA transport, 
which was not affected in this study, may be mediated by FABP5 because among the 
FABP family, FABP5 has been reported to bind preferentially with saturated fatty acids 
(Hanhoff et al., 2002). 
Figure 24: Mechanism of fatty acid Transport across the syncytiotrophoblast cells. 
Model of placental fatty acid transport through trophoblast cells. A complex interplay of 
different fatty acid transport proteins orchestrates fatty acid uptake mechanism. Within 
the cells NEFA are bound by different FABPs and have multiple functions like ferrying 
function, energy generation, TG and eicosanoid synthesis and activation of nuclear 
transcription factors like PPAR/RXR. Secretion and efflux of cholesterol out of 
trophoblasts. Cholesterol can exit cells as lipoproteins, with apolipoproteins, or by being 
effluxed to acceptors. Efflux can occur by aquous diffusion, scavenger receptor class B 
type 1 (SR-B1) or ATP-binding cassette transporter A1 (ABCA1), LP; lipoprotein, LPL; 
lipoprotein lipase, NEFA; non-esterified fatty acid, FATP, fatty acid transport protein, 
FAT; fatty acid translocase, p-FABPpm; placental plasma membrane FABP, PPAR; 
peroxisome proliferator activated receptor, RXR; retinoid X receptor. [Figure was 
modified from Hanebutt et al., 2008 and Woollett, 2004]. 
Most importantly, the Fabp3-KO placenta showed significantly impaired 
PUFA transport, to the extent that the Fabp3-KO fetuses had a lower accumulation of 
PUFAs than the wild-type. PUFAs are used not only as key components of 
biomembranes, but also play important roles in cell integrity, development, and 
maintenance. PUFAs are the precursors of important molecules, such as prostaglandins, 
leukotrienes, and thromboxanes, and they also represent a source of energy. The fetus 
mostly needs essential FAs and their derivatives, arachidonic acid (AA, 20:4n-6) and 
docosahexaenoic acid (DHA, 22:6n-3). Intrauterine requirements for essential FAs 
(derivatives of n-6 and n-3) during the last trimester of pregnancy through to the early 
weeks of life have been estimated to be 400 and 50 mg/(kg . d) for n-6 and n-3 FAs, 
respectively (Clandinin et al., 1981). Nevertheless, Fabp3-deficient placentas and 
fetuses achieved a similar weight to those of the wild-type mouse (data not shown), 
despite a marked impairment in FA transport. In this study, Fabp3-deficient placenta 
became more efficient in glucose transportation. Thus, it is likely that increased 
placental transport of glucose compensates for the decrease in PUFA transport. In other 
words, Fabp3-deficient conceptuses modified their metabolism to accommodate the 
lower availability of PUFAs for cell integrity and development, and as an energy source, 
as observed previously in Fabp3-deficient cardiac myocytes (Binas et al., 1999; Schaap
et al., 1999; Binas et al., 2007). 
During prenatal development, adequate supplies of FAs are so essential that the 
placenta doubles the levels circulating in the maternal plasma (Crawford 2000) and 
severe deficits may have permanent effects if they occur during critical periods of early 
development. AA is crucial to brain growth and mild deficiencies are associated with 
low birth weight and reduced head circumference (van de Lagemaat et al., 2011). AA 
also plays a key role in the cellular processes underlying learning and memory (Auestad
et al., 2003; Das et al., 2003). DHA is particularly concentrated in highly active 
membranes, such as synapses and photoreceptors, and adequate supplies are essential 
for normal visual and cognitive development (Uauy et al., 2001). Increasing evidence 
indicates that PUFA deficiencies or imbalances are associated with childhood 
developmental and psychiatric disorders, including attention deficit hyperactivity 
disorder (ADHD), dyslexia, dyspraxia, and autistic spectrum disorders(Richardson 
2004). These conditions show a high clinical overlap and run in the same families, as 
well as showing associations with various adult psychiatric disorders in which FA 
abnormalities are already implicated, such as depression, other mood disorders, and 
schizophrenia. Recently, we have revealed that the Fabp3-KO mouse shows a lower 
responsiveness to methamphetamine-induced sensitization and enhanced 
haloperidol-induced catalepsy, compared with the wild-type mouse (Shioda et al., 2010). 
It is thus interesting to note the possibility that such altered behavioral responses 
detected in the Fabp3-KO mouse may be partly attributed to a deficiency of Fabp3 in 
the placenta during the gestation period. 
CONCLUSION 
In summary, we have provided the first direct evidence of the detailed distribution of 
the FABP family in the mouse placenta. Despite there being no compensatory 
expression of FA transporters in vivo and impaired placental PUFA transport, 
Fabp3-deficient placentas are able to achieve litters of normal birth weight. However, 
the decreased FA nutrient transport and increased glucose transport suggest that 
Fabp3-null conceptuses have been growing with a modified nutrient mixture and may 
have undergone metabolic reprogramming. To understand the in vivo consequences of 
altered PUFA transport through the Fabp3-deficient placenta, detailed long-term health 
follow-up studies are warranted, as suggested by the evidence for the developmental 








In many ways, graduate school is like a long distance hike. With bug bites and twisted 
ankles, yet also summits and beautiful sunsets, my journey’s end is finally in sight. I 
would like to express my gratitude to all those who have helped me along my way. 
First, I would like to thank my advisor, Dr. Yuji Owada, for his guidance. Dr. 
Owada has trained me to think critically and to aptly communicate my data and ideas. 
My work in Dr. Owada’s lab has provided me with many skills and experiences that 
have defined me as a scientist and will aid me in my future career. 
I would also like to thank my thesis evaluation committee, -------------------, and 
----------------. Their useful advice has helped me to develop my project and to 
strengthen my training. 
I am grateful to all of the members of Dr. Owada’s lab, both past and present. 
To Dr. Kazem Sharifi, for knowing the answer to practically everything and for always 
being available to help. To Dr. Linda Koshy Vaidyan, for her advice on all things 
related to qPCR analysis. To Dr. Yasuhiro Adachi, for teaching me many lab techniques 
related to RT-PCR and cell culture. To Dr. Tomoo Sawada for his superb advice for 
staining and imaging techniques. To Dr. Tuerhong Tuerxun for his excellent teaching 
on the protein research techniques. To Mr. Yoshiteru Kagawa, for his hardworking style, 
getting me to think, and for trying to make me tougher.  
To Mr. Hirofumi Miyazaki, for all of our chats on science and on life. To Dr. 
Nobuko Tokdua, for taking me under her wing during my first years in the lab and 
teaching me several techniques. To Dr. Yui Yamamoto, Mr. Majid Ebrahimi and Dr. 
Yuki Yasumoto for all of their scientific advice and for making lab fun. I will miss all 
of you! 
I would also like to thank many of my related research laboratories including 
radioisotope research centre, gene research centre, biomedical research centre and 
animal centre for their permission and guidance to my work. Special thanks to Dr. 
Mahbub Hossain, Department of Hygiene, for his excellent teaching on bio-statistics. 
I would like to thank my family and friends. Thank you, Mom, Dad, and Ayrin, 
for always being with me, for believing in me, and for helping me to become the person 
I am today. Thanks to Dr. Nabiul Islam, Dr. Azizul Moqsud, Dr. Mahbub Hossain and 
their family; running buddy from my country who were always with me in my happy 
times and nightmares. 
Finally, I would like express my deep gratitude to Tomomi Tsumori, Mikie 
Okii and Masakatsu Tamechika for their assistance which prepared me possible to stay 
in Japan. Many many thanks to all labmembers including Saki Kawamura, Takanori 
Kodama, Tomonori Hara, Tatsuya Terasaki, Kota Ebisui, Motoki Sakai for all of your 
love and for supporting me in many ways, whether attending in my journal club 
presentation, listening to a practice seminar, or taking my mind of off work with several 
gifts. I can’t wait for more. I love you all very much. I will miss you all. 
